Surgical Robotics Technology

New Clinical Studies Show Benefits of Accuray CyberKnife® in Treatment of Neurological Indications

cyberknife-robotic-radiotherapy

Accuray Incorporated has announced that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company’s CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery. The data highlight the benefits experienced by neurosurgeons for more than two decades, including the ability to effectively and efficiently deliver radiation in single and multi-fraction sessions, treat benign and functional cases, primary brain and spine tumors and metastases, as well as previously irradiated tumors.

“We are proud to see the impact that CyberKnife technology has on advancing patient care, with nearly 50 abstracts presented at the ISRS conference showcasing the system’s use for non-invasive radiosurgery treatments. The data indicate we are fulfilling our goal to offer clinicians the tools they need to enhance the quality of care they offer and provide additional treatment options to their patients,” said Suzanne Winter, president and chief executive officer of Accuray.

Ms. Winter continued, “The CyberKnife platform continues to evolve with powerful enhancements that enable clinicians to continue delivering extremely precise and accurate radiosurgery treatments, while also significantly reducing treatment times, providing a more comfortable experience for patients and enabling medical care teams to treat more patients each day. But we are not stopping here. Through investments in research and development and industry partnerships we will continue to introduce best-in-class innovations that make an incredible system even better.”

New CyberKnife System Data: Helping to Make a Clinical Difference for Patients in as little as 1 to 5 Treatments

The CyberKnife System delivers frameless radiosurgery treatments, unlike other systems that use a fixed metal frame attached to the patient’s head to prevent movement during treatment. It provides clinical teams with a device that maximizes patient comfort and can deliver precision treatments in a single session, as well as up to 5 ultra-hypofractionated treatments, expanding access to radiosurgery to more patients. Studies shared at the ISRS meeting indicate radiosurgery delivered with the CyberKnife System can:

  • Provide excellent local control with very low toxicity when treating perioptic meningiomas, tumors that are challenging to treat because of their close proximity to critical brain structures impacting a person’s vision1
  • Offer a feasible and effective technique for treating patients who have previously received radiation treatment for recurrent primary brain tumors and metastases – indications with limited treatment options2
  • Supply an effective treatment approach for patients with craniopharyngioma, a slow growing brain tumor, with no evidence of long-term complications such as deterioration of visual or neuroendocrine function3
  • Provide clinical teams with an effective single fraction or ablative option, with low toxicity, for the post-operative treatment of brain metastases4 

The CyberKnife System is the industry’s only radiation delivery system that features a linear accelerator (linac) directly mounted onto a sophisticated robotic platform to deliver radiation therapy. The robot maneuvers around the patient to deliver multiple beams of radiation from thousands of angles to target the tumor or lesion. Using advanced imaging and Accuray proprietary Synchrony® technology, the system can see the tumor or lesion in the brain and continually verifies its position, automatically correcting and adapting the beam position for even the slightest movement. For example, if the patient moves their head during treatment, the CyberKnife® System detects this movement and synchronizes the treatment target to the new position in real-time delivering maximum dose directly to the tumor while minimizing dose to surrounding health tissue, reducing the risk of many common side effects.

[1] ORAL PRESENTATIONS Skull-base Societies Session: Meningiomas; OP14 PERIOPTIC MENINGIOMAS TREATED WITH CYBERKNIFE RADIOSURGERY (1 – 5 SESSIONS): CLINICAL RESULTS. Morena SALLABANDA (Madrid, Spain), Kita SALLABANDA. https://isrscongress.org/real-time-programme-expanded/

[2] 01. EPOSTERS – BRAIN – MALIGNANT; P023 Re-irradiation of relapsed intracranic lesions with stereotactic radiotherapy: a monoinstitutional experience. Stefano Lorenzo VILLA (Milan, Italy), Chiara Lucrezia DEANTONI, Andrei FODOR, Roberta TUMMINERI, Flavia ZERBETTO, Sara BROGGI, Jessica SADDI, Barbara LONGOBARDI, Antonella DEL VECCHIO, Italo DELL’OCA, Nadia Gisella DI MUZIO. https://isrscongress.org/eposters/

[3] 02. EPOSTERS – BRAIN – BENIGN; P089 Long term results in stereotactic radiosurgery for craniopharyngioma: monoinstitutional experience. Sara MORLINO (Milano, Italy), Marcello MARCHETTI, Valentina PINZI, Irene CANE, Maria Luisa FUMAGALLI, Laura FARISELLI. https://isrscongress.org/eposters/

[4] 01. EPOSTERS – BRAIN – MALIGNANT; P034 Stereotactic radiosurgery (SRS) and fractionated stereotactic radiosurgery (fSRS) as adjuvant treatment for resected brain metastases (BMs): a single-center series. Valentina PINZI (Milan, Italy), Anna ROMEO, Marcello MARCHETTI, Sara MORLINO, Irene TRAMACERE, Laura FARISELLI. https://isrscongress.org/eposters/

Cision View content to download multimedia:https://www.prnewswire.com/news-releases/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment-of-neurological-indic

Source: Accuray Incorporated.

Surgical Robotics Technology

Join thousands of Surgical Robotics Experts and get the latest updates straight to your inbox!